111 related articles for article (PubMed ID: 8668164)
1. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
Knaus PI; Lindemann D; DeCoteau JF; Perlman R; Yankelev H; Hille M; Kadin ME; Lodish HF
Mol Cell Biol; 1996 Jul; 16(7):3480-9. PubMed ID: 8668164
[TBL] [Abstract][Full Text] [Related]
2. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.
Rotzer D; Roth M; Lutz M; Lindemann D; Sebald W; Knaus P
EMBO J; 2001 Feb; 20(3):480-90. PubMed ID: 11157754
[TBL] [Abstract][Full Text] [Related]
3. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily.
Radaev S; Zou Z; Huang T; Lafer EM; Hinck AP; Sun PD
J Biol Chem; 2010 May; 285(19):14806-14. PubMed ID: 20207738
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Lynch MA; Petrel TA; Song H; Knobloch TJ; Casto BC; Ramljak D; Anderson LM; DeGroff V; Stoner GD; Brueggemeier RW; Weghorst CM
Gene Expr; 2001; 9(4-5):157-71. PubMed ID: 11444526
[TBL] [Abstract][Full Text] [Related]
5. An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling.
Kim SK; Barron L; Hinck CS; Petrunak EM; Cano KE; Thangirala A; Iskra B; Brothers M; Vonberg M; Leal B; Richter B; Kodali R; Taylor AB; Du S; Barnes CO; Sulea T; Calero G; Hart PJ; Hart MJ; Demeler B; Hinck AP
J Biol Chem; 2017 Apr; 292(17):7173-7188. PubMed ID: 28228478
[TBL] [Abstract][Full Text] [Related]
6. TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin cells according to distinct levels of TbetaRII expression.
Bandyopadhyay B; Han A; Dai J; Fan J; Li Y; Chen M; Woodley DT; Li W
J Cell Sci; 2011 Jan; 124(Pt 1):19-24. PubMed ID: 21172820
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.
Tokizaki S; Podyma-Inoue KA; Matsumoto T; Takahashi K; Kobayashi M; Ibi H; Uchida S; Iwabuchi S; Harada H; Hashimoto S; Miyazono K; Shirouzu M; Watabe T
Cancer Sci; 2024 Jan; 115(1):211-226. PubMed ID: 37972575
[TBL] [Abstract][Full Text] [Related]
8. Peptide ligands that use a novel binding site to target both TGF-β receptors.
Li L; Orner BP; Huang T; Hinck AP; Kiessling LL
Mol Biosyst; 2010 Dec; 6(12):2392-402. PubMed ID: 20890540
[TBL] [Abstract][Full Text] [Related]
9. Computational modeling of TGF-β2:TβRI:TβRII receptor complex assembly as mediated by the TGF-β coreceptor betaglycan.
Madamanchi A; Ingle M; Hinck AP; Umulis DM
Biophys J; 2023 Apr; 122(7):1342-1354. PubMed ID: 36869592
[TBL] [Abstract][Full Text] [Related]
10. IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver.
Liu C; Billadeau DD; Abdelhakim H; Leof E; Kaibuchi K; Bernabeu C; Bloom GS; Yang L; Boardman L; Shah VH; Kang N
J Clin Invest; 2013 Mar; 123(3):1138-56. PubMed ID: 23454766
[TBL] [Abstract][Full Text] [Related]
11. Chimeric TβRII-SE/Fc overexpression by a lentiviral vector exerts strong antitumoral activity on colorectal cancer-derived cell lines in vitro and on xenografts.
Romo A; Rodríguez TM; Yu G; Dewey RA
Cancer Gene Ther; 2024 Jan; 31(1):174-185. PubMed ID: 37993543
[TBL] [Abstract][Full Text] [Related]
12. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Zhao W; Kobayashi M; Ding W; Yuan L; Seth P; Cornain S; Wang J; Okada F; Hosokawa M
Cancer Immunol Immunother; 2002 Sep; 51(7):381-8. PubMed ID: 12192538
[TBL] [Abstract][Full Text] [Related]
13. TGM6, a helminth secretory product, mimics TGF-β binding to TβRII to antagonize TGF-β signaling in fibroblasts.
White SE; Schwartze TA; Mukundan A; Schoenherr C; Singh SP; van Dinther M; Cunningham KT; White MPJ; Campion T; Pritchard J; Hinck CS; Ten Dijke P; Inman G; Maizels RM; Hinck AP
bioRxiv; 2023 Dec; ():. PubMed ID: 38187573
[TBL] [Abstract][Full Text] [Related]
14. Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R; Huang GM
J Bone Oncol; 2023 Dec; 43():100513. PubMed ID: 38021074
[TBL] [Abstract][Full Text] [Related]
15. A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling.
Petersen SH; Al Badawy K; Hopkins R; Vu DL; Rahmani M; Maia SMP; Connolly JE
Mol Ther Oncolytics; 2023 Dec; 31():100730. PubMed ID: 37829123
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.
Medina-Echeverz J; Vasquez M; Gomar C; Ardaiz N; Berraondo P
Cancer Immunol Immunother; 2015 Jun; 64(6):717-25. PubMed ID: 25795134
[TBL] [Abstract][Full Text] [Related]
17. Directed Blocking of TGF-β Receptor I Binding Site Using Tailored Peptide Segments to Inhibit its Signaling Pathway.
Sepehri S; Arab SS; Behmanesh M; H Sajedi R
Iran J Biotechnol; 2020 Jan; 18(1):e2561. PubMed ID: 32884960
[TBL] [Abstract][Full Text] [Related]
18. The helminth TGF-β mimic TGM4 is a modular ligand that binds CD44, CD49d and TGF-β receptors to preferentially target myeloid cells.
Singh SP; Smyth DJ; Cunningham K; Mukundan A; Byeon CH; Hinck CS; White MPJ; Ciancia C; Wosowska N; Sanders A; Jin R; Lilla S; Zanivan S; Schoenherr C; Inman G; van Dinther M; Ten Dijke P; Hinck AP; Maizels RM
bioRxiv; 2023 Nov; ():. PubMed ID: 38014296
[TBL] [Abstract][Full Text] [Related]
19. Expanding the Chemical Space of Transforming Growth Factor-β (TGFβ) Receptor Type II Degraders with 3,4-Disubstituted Indole Derivatives.
Längle D; Wojtowicz-Piotrowski S; Priegann T; Keller N; Wesseler F; Reckzeh ES; Steffens K; Grathwol C; Lemke J; Flasshoff M; Näther C; Jonson AC; Link A; Koch O; Di Guglielmo GM; Schade D
ACS Pharmacol Transl Sci; 2024 Apr; 7(4):1069-1085. PubMed ID: 38633593
[TBL] [Abstract][Full Text] [Related]
20. Metapopulation dynamics and spatial heterogeneity in cancer.
González-García I; Solé RV; Costa J
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13085-9. PubMed ID: 12351679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
